Corinne Godin

ORCID: 0000-0002-8350-4241
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ferroptosis and cancer prognosis
  • Cell death mechanisms and regulation
  • Cancer, Lipids, and Metabolism
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Endoplasmic Reticulum Stress and Disease
  • Ubiquitin and proteasome pathways
  • Protein Degradation and Inhibitors
  • RNA Interference and Gene Delivery
  • Drug Transport and Resistance Mechanisms
  • Trace Elements in Health
  • Melanoma and MAPK Pathways
  • Lung Cancer Treatments and Mutations
  • Cancer Mechanisms and Therapy
  • ATP Synthase and ATPases Research
  • Genomics, phytochemicals, and oxidative stress
  • Neuroblastoma Research and Treatments
  • Phagocytosis and Immune Regulation
  • Lung Cancer Research Studies
  • French Urban and Social Studies
  • Bone health and treatments
  • Blood Coagulation and Thrombosis Mechanisms
  • Autophagy in Disease and Therapy
  • Advanced Glycation End Products research
  • HER2/EGFR in Cancer Research
  • Bone Metabolism and Diseases

Université de Picardie Jules Verne
2013-2024

Chirurgie et extrémité céphalique, caractérisation morphologique et fonctionnelle
2020-2024

Centre de Biologie du Développement
2023

Laboratoire de Biochimie Théorique
2016-2018

Centre Hospitalier Universitaire Amiens-Picardie
2013-2017

Inserm
2010-2013

Hôpital Nord
2012

The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC). In our report, we examined cytotoxic effects on HCC cells. We report that depletion intracellular iron stores achieved by using chelator deferoxamine (DFX) strikingly protects cells from sorafenib. protective effect could not be explained an interference with conventional forms programmed cell death, such as apoptosis or autophagic death. also found DFX did prevent...

10.1002/ijc.28159 article EN International Journal of Cancer 2013-03-18

Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma (HCC), but it not known whether sorafenib equally active in all HCC. Here, our aim was to explore intrinsic differences response HCC cells sorafenib, identify potential mechanisms leading primary resistance this treatment. We analyzed a panel six human cell lines and compared activity main oncogenic kinase cascades, their clonogenic potential, proliferation apoptosis upon exposure sorafenib. report that...

10.1002/ijc.27604 article EN International Journal of Cancer 2012-04-19

Sorafenib, a kinase inhibitor active against various solid tumours, induces oxidative stress and ferroptosis, new form of necrosis, in some cancer cells. Clinically-applicable biomarkers that reflect the impact sorafenib on redox metabolism cells are lacking.We used gene expression microarrays, real-time PCR, immunoblot, protein-specific ELISA, reporter constructs encoding enzyme luciferase to study response panel sorafenib. Tumour explants prepared from surgical hepatocellular carcinoma...

10.1186/s12943-016-0526-2 article EN cc-by Molecular Cancer 2016-05-16

Strontium ranelate exerts both an anticatabolic and anabolic effect on bone cells. To further investigate the mechanism by which strontium inhibits resorption, effects of varying concentrations Sr<sub>o</sub><sup>2+</sup> osteoclastic differentiation were studied using RAW 264.7 cells peripheral blood monocytic (PBMCs). We report that increasing down-regulate tartrate-resistant acid phosphatase activity, leading to inhibition resorption (−48% when PBMCs cultured for 14 days in presence 2 mM...

10.1124/mol.109.063347 article EN Molecular Pharmacology 2010-06-28

Proteins of the BCL2 family are key regulators apoptosis. Their expression levels frequently altered in cancers, enabling tumor cells to survive. To gain insight into pathogenesis hepatocellular carcinoma (HCC), we performed a comprehensive survey members samples obtained from surgically resected HCCs. Here, report occurrence new molecular anomaly, consisting strong reduction proapoptotic protein BAD HCC compared with surrounding nontumoral tissue. We investigate function panel cell lines....

10.1158/1541-7786.mcr-10-0029 article EN Molecular Cancer Research 2010-07-21

Sorafenib is the first line treatment for advanced hepatocellular carcinoma (HCC). We explored its impact on proteostasis of cancer cells, i.e. processes that regulate synthesis, maturation and turn-over cellular proteins. observed sorafenib inhibits production tumour marker alpha-foetoprotein (AFP) in two different HCC cell lines, an effect correlated with a radical inhibition protein biosynthesis. This was at clinically relevant concentrations not related to transport amino acids across...

10.18632/oncotarget.23843 article EN Oncotarget 2018-01-03

Abstract Uremic syndrome is attributed to the progressive retention of a large number compounds, such as indoxyl sulfate, which under physiological conditions are excreted by kidneys. Previous in vitro studies have demonstrated that uremic sulfate concentrations induce weak increase proliferation both rat and human vascular aortic smooth muscle cells (hVASMC) after short term exposition toxin (i.e. 24 h). In present study, we evaluated effects on hVASMC at three different long‐term exposure...

10.1111/j.1744-9987.2010.00885.x article EN Therapeutic Apheresis and Dialysis 2011-01-25

The tumor microenvironment is an important determinant of glioblastoma (GBM) progression and response to treatment. How oncogenic signaling in GBM cells modulates the composition its activation unclear. We aimed explore potential local immunoregulatory function ERK1/2 GBM. Using proteomic transcriptomic data (RNA seq) available for tumors from Cancer Genome Atlas (TCGA), we show that with high levels phosphorylated have increased infiltration tumor-associated macrophages (TAM) a...

10.1042/bsr20191433 article EN Bioscience Reports 2019-08-29

The immune checkpoint molecule PD-L1 (CD274) is a crucial regulator of the tumor response. Its expression has been reported in therapeutic context Head and Neck Squamous Cell Carcinoma (HNSCC), but it remains unclear how therapeutically approved molecules regulate HNSCC cells. Three cell lines (BICR6, PE/CA-PJ34 PE/CA-PJ41) were used to analyze by immunoblotting, immunofluorescence QPCR. Freely-available single RNAseq data from also used. 5-Fluorouracil (5-FU) increased with high efficacy...

10.1016/j.tranon.2021.101110 article EN cc-by Translational Oncology 2021-05-02

How tumors regulate the genes of coagulome is crucial for cancer-associated thrombosis and occurrence venous thromboembolic complications in patients with cancer. We have previously reported potent yet complex effects glucocorticoids (GC) on expression three that play a key role regulation thrombin/plasmin activation (F3, PLAU, SERPINE1). This study aimed to extend investigation GC whole tumor assess resulting impact ability cancer cells activate thrombin plasmin.

10.21873/anticanres.17145 article EN cc-by-nc-nd Anticancer Research 2024-07-26

The proteins of the B-cell lymphoma 2 (Bcl-2) family are important regulators apoptosis under normal and pathological conditions. Chemical compounds that block antiapoptotic this have been introduced, such as 4-[4-[(4′-Chloro[1,1′-biphenyl]-2-yl)methyl]-1-piperazinyl]-<i>N</i>-[[4-[[(1<i>R</i>)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide (ABT-737), a BH3-mimetic neutralizes Bcl-2 Bcl-xL. In study, we used ABT-737 to explore dynamic regulation in...

10.1124/mol.110.070565 article EN Molecular Pharmacology 2011-03-10

Background: The coagulome, defined as the repertoire of genes that locally regulate coagulation and fibrinolysis, is a key determinant vascular thromboembolic complications cancer. In addition to complications, coagulome may also tumor microenvironment (TME). Glucocorticoids are hormones mediate cellular responses various stresses exert anti-inflammatory effects. We addressed effects glucocorticoids on human tumors by investigating interactions with Oral Squamous Cell Carcinoma, Lung...

10.3390/cancers15051531 article EN Cancers 2023-02-28

Background/Aim: Organ transplant patients treated with the immunosuppressive drug cyclosporine A often present malignant kidney tumors. Cyclosporine can promote oncogenesis in a cell-intrinsic manner by increasing production of vascular endothelial growth factor (VEGF). Materials and Methods: We explored impact role unfolded protein response (UPR) on three human renal cell carcinoma (RCC) lines under normoxic hypoxic (1% O<sub>2</sub>) conditions. Results: regulated expression VEGF at...

10.21873/anticanres.11416 article EN Anticancer Research 2017-03-17

Sorafenib increases the expression levels of MT1B in Huh7 cells. Figure S2: Pharmacological antioxidants prevent induction induced by sorafenib. Table S1: List genes upregulated cells exposed to sorafenib (10 μM) for 9 h. Summary characteristics hepatocellular carcinoma tumours used short-term culture tumour explants. S3: clinical HCC patients two cohorts. (DOC 185 kb)

10.6084/m9.figshare.c.3698305_d1 article EN 2016-01-01
Coming Soon ...